.png)
.png)
ABSTRACT
Many patients with diabetes mellitus show increased platelet aggregation and prostaglandin synthesis m response to adenosine diphosphate (ADP) when their platelets are tested in platelet-rich plasma or washed platelet suspensions. In this study, the effect of type 2 diabetes on in-vitro platelet aggregation induced by various agonists (ADP, collagen, epinephrine) was investigated in coronary artery disease patients (CAD). Thirty type 2 diabetes and 40 non-diabetes patients with CAD were studied to investigate the effects of type 2 diabetes mellitus on the response to ADP, collagen and epinephrine induced in-vitro platelet aggregation. Two parameters were used to evaluate the aggregation activity of platelets: the degree of aggregation ratio and aggregation duration. Platelet-rich plasma samples were obtained from the patients, and were treated with in-vitro ADP (10 µmol/L), collagen (0.6 mgm/ml) and epinephrine (20 µmol/L) and platelet aggregation slopes were calculated via the turbidimetric method of Born. The aggregation ratio (%) and the duration (sec.) in the study cases were measured from these slopes and data were compared by the Student's t test. The ratio and duration of platelet aggregation which are induced by agonists were significantly greater in the type 2 diabetes group than the non-diabetic group (p<0.05, p<0.01 for ADP, p<0.05, p<0.05 for collagen and p<0.01 and p<0.05 for epinephrine) respectively. Agonist-induced in-vitro platelet aggregation response was higher in patients with type 2 diabetes than in non-diabetes. This makes us think that, diabetic CAD patients may need more potent antiplatelet therapy, and blood glucose levels need to be optimally regulated.
Many patients with diabetes mellitus show increased platelet aggregation and prostaglandin synthesis m response to adenosine diphosphate (ADP) when their platelets are tested in platelet-rich plasma or washed platelet suspensions. In this study, the effect of type 2 diabetes on in-vitro platelet aggregation induced by various agonists (ADP, collagen, epinephrine) was investigated in coronary artery disease patients (CAD). Thirty type 2 diabetes and 40 non-diabetes patients with CAD were studied to investigate the effects of type 2 diabetes mellitus on the response to ADP, collagen and epinephrine induced in-vitro platelet aggregation. Two parameters were used to evaluate the aggregation activity of platelets: the degree of aggregation ratio and aggregation duration. Platelet-rich plasma samples were obtained from the patients, and were treated with in-vitro ADP (10 µmol/L), collagen (0.6 mgm/ml) and epinephrine (20 µmol/L) and platelet aggregation slopes were calculated via the turbidimetric method of Born. The aggregation ratio (%) and the duration (sec.) in the study cases were measured from these slopes and data were compared by the Student's t test. The ratio and duration of platelet aggregation which are induced by agonists were significantly greater in the type 2 diabetes group than the non-diabetic group (p<0.05, p<0.01 for ADP, p<0.05, p<0.05 for collagen and p<0.01 and p<0.05 for epinephrine) respectively. Agonist-induced in-vitro platelet aggregation response was higher in patients with type 2 diabetes than in non-diabetes. This makes us think that, diabetic CAD patients may need more potent antiplatelet therapy, and blood glucose levels need to be optimally regulated.